Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2019-10-17 Regulatory Filings
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
BioPorto submits answers to the FDA regarding The NGAL Test™ for risk assessment for AKI in pediatric patients
Regulatory Filings Classification · 95% confidence The document is a short announcement (2079 characters) from BioPorto regarding a regulatory update concerning their FDA application for 'The NGAL Test'. It does not constitute a full legal report, financial statement, or proxy statement. As it is a specific regulatory update regarding a product application and does not fit into the other specialized categories like M&A or Board changes, it is best classified as a general regulatory announcement.
2019-10-17 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a short announcement dated October 17, 2019, detailing BioPorto's submission of answers to the FDA regarding its NGAL Test application. It references a previous 'Interim Report for the Second Quarter of 2019' but the content itself is an update on regulatory interaction (FDA submission/response) and not the full report. Since it is a specific regulatory update concerning legal/procedural matters with a government body (FDA) and does not fit clearly into ER, IR, or 10-K, it is best classified as a general Regulatory Filing (RNS). Given the short length and the nature of updating on a regulatory process, RNS is the most appropriate general category, although LTR (Legal Proceedings Report) could be considered if the FDA interaction was adversarial, but RNS is safer for general regulatory updates.
2019-10-17 English
Updated Financial calendar for 2019 and Financial calendar for 2020
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1719 characters) titled 'Updated Financial calendar for 2019 and Financial calendar for 2020'. It lists future dates for the release of various reports (Interim, Annual) and meetings (AGM). It does not contain the actual financial reports themselves, but rather serves as a notification of the schedule for their publication. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2019-09-06 English
Updated Financial calendar for 2019 and Financial calendar for 2020
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1719 characters) titled 'Updated Financial calendar for 2019 and Financial calendar for 2020'. It lists future dates for the release of various reports (Interim, Annual) and meetings (AGM). It does not contain the actual financial reports themselves, but rather serves as a notification of the schedule for their publication. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2019-09-06 English
Updated Financial calendar for 2019 and Financial calendar for 2020
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1719 characters) titled 'Updated Financial calendar for 2019 and Financial calendar for 2020'. It lists future dates for the release of various reports (Interim, Annual) and meetings (AGM). It does not contain the actual financial reports themselves, but rather serves as a notification of the schedule for their publication. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2019-09-06 English
Updated Financial calendar for 2019 and Financial calendar for 2020
Report Publication Announcement Classification · 98% confidence The document is titled 'Updated Financial calendar for 2019 and Financial calendar for 2020' and lists future dates for various corporate events, including the release of the 'Annual Report 2019', 'Interim Report' releases, and the 'Annual General Meeting'. It does not contain the content of any of these reports but rather announces *when* they will be published. According to Rule 2 (The 'MENU VS MEAL' Rule), a document that announces the publication of other reports, especially when it is short (1690 characters) and includes an attachment link, should be classified as a Report Publication Announcement (RPA).
2019-09-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.